About Us
37 Years of Know-How and continuing to innovate to stay on the leading edge
At Alpex Pharma, we develop and manufacture innovative pharmaceutical drugs and nutritional products. Our developments include pharmaceutical drugs and products while simultaneously developing the innovative and patented technologies used for their administration.
Our drug delivery systems and dosage forms maximize the utility drawn from API’s (Active Pharmaceutical Ingredients) present in the administered drugs, promoting successful treatments based on precise dosage and efficient delivery. An efficiency which in turn, gives more control to medical practitioners, as well as a reduced need for redundancy during manufacture.
We are an integrated pharma company. And in addition to our key activities, we provide a wide range of services to our clients and partners. doing so with an unflinching focus on quality and reliability. Our high production capacities and advanced R&D technologies make us one of the most important companies in the field of fast-melt ODT’s (oral dissolving tablets) in the world.
With 100+ pharma patents, we have commercialized over 150 different products, and successfully established ourselves as a reference in the healthcare industry with more than 200 million units sold annually. A Switzerland based global company, our pharmaceuticals, novel medicines, nutraceuticals, delivery systems, are sold all over the world and in the most developed and demanding global markets. By operating in a highly regulated sector, we adopt a high-watermark approach to compliance to ensure that we exceed the requirements of all applicable international standards.
Our Journey So Far
With 100+ pharma patents, we have commercialized over 150 different products, and successfully established ourselves as a reference in the healthcare industry with 200 million units sold annually. We sell our pharmaceuticals, novel medicines, nutraceuticals, delivery systems, and APIs in global markets. And by operating in a highly regulated sector, we adopt a high-watermark approach to compliance to ensure that we exceed the requirements of all applicable international standards.
1988
1992
1998
2004
2007
2010
2012
2013
2015
2016
2017
2018
2019
2020
2021
Start of the Company as Aesculapius Pharma with focus on effervescent formulations.
Acquisition by Élan Pharma - A Global Pharma Multinational listed in New York and London.
First fast-melt product commercialized.
Acquisition of majority shares by Sanders, Morris, Harris (SMH) funds – USA. Changed name to Alpex Pharma SA.
Capital increase and BB Biotech Ventures joins Alpex’ shareholder base.
Registration of Narcotic Tablet in Germany.
Launching of Phentermine ODT in USA.
Launching of NAC ET in NL.
Launching of Acetylcysteine in USA.
Launching of NAC 600 mg ET in France, Macrogol in NL, and Ca & Vit D3 in NL.
Launching of Phentermine ODT in Mexico, and NAC 600 mg in UK.
Launching of Phentermine ODT in Mexico, and NAC 600 mg in UK.
Launching of Phentermine ODT in Mexico, and NAC 600 mg in UK.
Registration of Phentermine Citrate Buccal Tablet in Germany.
Registration of Phentermine Citrate Buccal Tablet in Germany.
Our Industry-Explicit Competence
We are an integrated pharma company. And in addition to our key activities, we provide a wide range of services to our clients and partners. doing so with an rigourous focus on quality and reliability. Our high production capacities and advanced R&D technologies make us one of the most important companies in the field of fast-melt ODT’s (oral dissolving tablets) in the world.